Want to see RLAY full AI Analyst Report?
Relay Therapeutics (RLAY) Stock Forecast & Price Target
636 Followers
RLAY Analyst Ratings
Strong Buy
8Buy0Hold0Sell
Based on 8 analysts giving stock ratings to Relay Therapeutics in the past 3 months
RLAY Stock 12 Month Forecast
Average Price Target
$27.29▲(60.50% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $27.29 with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a 60.50% change from the last price of $17.00.
Past 12 Months12 Month ForecastJan2026Oct2026
High$31.00
Average$27.29
Low$20.00
Highest Price TargetHighest$31.00Average Price Target$27.29Lowest Price TargetLowest$20.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | $30 | buy | 76.47%Upside | Reiterated | 11/05/26 | ||
| John Newman | Canaccord Genuity | $29 | buy | 70.59%Upside | Reiterated | 11/05/26 | ||
| Chi Meng Fong | Bank of America Securities | ― | buy | ― | Reiterated | 11/05/26 | ||
| Debjit Chattopadhyay | Guggenheim | $26 | buy | 52.94%Upside | Initiated | 10/27/26 | ||
| Boris Peaker | JonesTrading | $20 | buy | 17.65%Upside | Reiterated | 09/27/26 | ||
| Robert Burns | H.C. Wainwright | $28→$29 | buy | 70.59%Upside | Reiterated | 08/21/26 | ||
| Priyanka Grover | J.P. Morgan | $28→$31 | buy | 82.35%Upside | Reiterated | 08/14/26 | ||
| Silvan Tuerkcan | Citizens JMP | $21→$26 | buy | 52.94%Upside | Reiterated | 08/10/26 | ||
| Yaron Werber | TD Cowen | ― | buy | ― | Reiterated | 08/06/26 | ||
| Salveen Richter | Goldman Sachs | $22→$31 | buy | 82.35%Upside | Reiterated | 07/20/26 | ||
| Sean McCutcheon | Raymond James | $23→$26 | buy | 52.94%Upside | Reiterated | 05/19/26 | ||
| Eva Fortea Verdejo | Wells Fargo | $21 | buy | 23.53%Upside | Reiterated | 05/19/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Etzer DaroutBarclays | BuyReiterated$30 | 11/05/26 | 76.47%Upside | ||
| John NewmanCanaccord Genuity | BuyReiterated$29 | 11/05/26 | 70.59%Upside | ||
| Chi Meng FongBank of America Securities | BuyReiterated | 11/05/26 | ― | ||
| Debjit ChattopadhyayGuggenheim | BuyInitiated$26 | 10/27/26 | 52.94%Upside | ||
| Boris PeakerJonesTrading | BuyReiterated$20 | 09/27/26 | 17.65%Upside | ||
| Robert BurnsH.C. Wainwright | BuyReiterated$28→$29 | 08/21/26 | 70.59%Upside | ||
| Priyanka GroverJ.P. Morgan | BuyReiterated$28→$31 | 08/14/26 | 82.35%Upside | ||
| Silvan TuerkcanCitizens JMP | BuyReiterated$21→$26 | 08/10/26 | 52.94%Upside | ||
| Yaron WerberTD Cowen | BuyReiterated | 08/06/26 | ― | ||
| Salveen RichterGoldman Sachs | BuyReiterated$22→$31 | 07/20/26 | 82.35%Upside | ||
| Sean McCutcheonRaymond James | BuyReiterated$23→$26 | 05/19/26 | 52.94%Upside | ||
| Eva Fortea VerdejoWells Fargo | BuyReiterated$21 | 05/19/26 | 23.53%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Relay Therapeutics
3 Months
Success Rate6/10 ratings generated profit
60%
Average Return
+9.00%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +9.00% per trade.
1 Year
Success Rate9/18 ratings generated profit
50%
Average Return
+62.64%
Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +62.64% per trade.
2 Years
Success Rate14/18 ratings generated profit
78%
Average Return
+155.86%
Copying Robert Burns's trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +155.86% per trade.
RLAY Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 3 | 3 | 3 | 3 |
| Buy | 10 | 14 | 11 | 12 | 6 |
| Hold | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 25 | 18 | 14 | 15 | 9 |
In the current month, RLAY has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 27.29.
RLAY Financial Forecast
High$-0.26
Consensus$-0.36
Low$-0.46
RLAY Earnings Forecast
Next quarter’s earnings estimate for RLAY is -$0.36 with a range of -$0.46 to -$0.26. The previous quarter’s EPS was -$0.37. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$27.2M
Consensus$5.88M
Low$0.00
RLAY Sales Forecast
Next quarter’s sales forecast for RLAY is $5.88M with a range of $0 to $27.20M. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
RLAY Stock Forecast FAQ
What is RLAY’s average 12-month price target, according to analysts?
Based on analyst ratings, Relay Therapeutics’s 12-month average price target is $27.29.
What is RLAY’s upside potential, based on the analysts’ average price target?
Relay Therapeutics has 60.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RLAY a Buy, Sell or Hold?
Relay Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Relay Therapeutics’s price target?
The average price target for Relay Therapeutics is $27.29. This is based on 8 12-month price targets, issued in the past 3 months. The highest analyst price target is $31.00, the lowest forecast is $20.00. The average price target represents a 60.50% increase from the current price of $17.
What do analysts say about Relay Therapeutics?
Relay Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of RLAY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
